IDEXX Laboratories, Inc. (NASDAQ:IDXX) Director M Anne Szostak sold 5,906 shares of the firm’s stock in a transaction dated Thursday, February 14th. The stock was sold at an average price of $208.96, for a total transaction of $1,234,117.76. Following the completion of the transaction, the director now owns 6,490 shares of the company’s stock, valued at $1,356,150.40. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website.
Shares of NASDAQ IDXX traded up $1.06 during mid-day trading on Tuesday, reaching $211.32. The company had a trading volume of 484,100 shares, compared to its average volume of 552,948. The firm has a market capitalization of $18.13 billion, a price-to-earnings ratio of 49.61 and a beta of 1.02. IDEXX Laboratories, Inc. has a 12-month low of $176.11 and a 12-month high of $256.22.
IDEXX Laboratories (NASDAQ:IDXX) last posted its quarterly earnings results on Friday, February 1st. The company reported $0.98 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.90 by $0.08. The business had revenue of $549.39 million during the quarter, compared to analyst estimates of $546.04 million. IDEXX Laboratories had a net margin of 17.03% and a negative return on equity of 1,501.97%. The firm’s revenue was up 8.5% compared to the same quarter last year. During the same period in the prior year, the firm earned $0.43 earnings per share. As a group, equities research analysts predict that IDEXX Laboratories, Inc. will post 4.69 EPS for the current fiscal year.
Several hedge funds and other institutional investors have recently bought and sold shares of the company. Pearl River Capital LLC bought a new position in IDEXX Laboratories during the fourth quarter valued at approximately $28,000. Sontag Advisory LLC bought a new position in IDEXX Laboratories during the fourth quarter valued at approximately $79,000. Quantamental Technologies LLC bought a new position in IDEXX Laboratories during the fourth quarter valued at approximately $92,000. Migdal Insurance & Financial Holdings Ltd. raised its position in IDEXX Laboratories by 144.3% during the third quarter. Migdal Insurance & Financial Holdings Ltd. now owns 618 shares of the company’s stock valued at $154,000 after acquiring an additional 365 shares in the last quarter. Finally, Ipswich Investment Management Co. Inc. bought a new position in IDEXX Laboratories during the fourth quarter valued at approximately $124,000. 87.41% of the stock is owned by institutional investors and hedge funds.
About IDEXX Laboratories
IDEXX Laboratories, Inc, together with its subsidiaries, develops, manufactures, and distributes products and services primarily for the companion animal veterinary, livestock and poultry, dairy, and water testing markets worldwide. It operates through Companion Animal Group; Water Quality Products; Livestock, Poultry and Dairy; and Other segments.
Recommended Story: How analysts view the yield curve
Receive News & Ratings for IDEXX Laboratories Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for IDEXX Laboratories and related companies with MarketBeat.com's FREE daily email newsletter.